
Yvonne Riley-Poku, PharmD
Advertisement
Articles by Yvonne Riley-Poku, PharmD


The agent is the first oral therapy for this indication.

Pharmacists can offer guidance on proper use of therapies and encourage adherence to regimens.

Patients with EGFR exon 20 insertion mutation NSCLC account for approximately 1%-2% of NSCLC cases.

Cholangiocarcinoma is a rare bile duct cancer, with physicians diagnosing approximately 8000 cases each year.

The American Cancer Society estimates that oncologists will diagnose about 34,920 new cases of multiple myeloma in 2021 with about 12,410 deaths expected to occur.
Advertisement
Latest Updated Articles
Oncology Overview: Infigratinib for Advanced CholangiocarcinomaPublished: August 24th 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Expert Discusses Logistical Considerations and Future Research Needs for Radiopharmaceuticals
2
Zongertinib Shows Clinically Meaningful Efficacy in Advanced HER2-Mutant NSCLC
3
A Common Virus May Hold New Clues to Lupus
4
When to Call, When to Counsel: Statin Drug Interactions
5






